Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


JenaValve Raises $62.5 Million To Fund Transfemoral TAVI Trial And More

This article was originally published in The Gray Sheet

Executive Summary

Funds will help the German company continue developing its JenaValve transcatheter aortic valve, including a new clinical trial of the transfemoral version of the system.

You may also be interested in...

Device/Diagnostics Quarterly Deal Statistics, Q3 2013

Device and diagnostics companies both suffered declines in fundraising compared with previous quarters. The biggest medtech acquisition was Stryker’s $1.4 billion buyout of MAKO, while in diagnostics BioMeriux’s $450 million purchase of BioFire topped the list.

VC Funding In 2013: Some Impressive Device Rounds, But Momentum Shifts To Biotech

Medtech start-ups have closed on some impressive venture capital funding rounds so far this year, with the largest investments concentrated in a few “hot” technology areas. But the biotechnology industry garnered far more VC funding in Q2 than did the medical device sector, particularly with regards to early-stage funding.

News Briefs: Health Care Spending; Boston Sci In Shanghai; New Products

CMS releases health care spending estimates. Boston Scientific opens new centers in Shanghai. New products from Crosstrees, Biotronik and JenaValve.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts